Compare STRIDES PHARMA SCIENCE with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs J.B.CHEMICALS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE J.B.CHEMICALS STRIDES PHARMA SCIENCE/
J.B.CHEMICALS
 
P/E (TTM) x 14.5 15.1 96.3% View Chart
P/BV x 0.9 2.1 41.2% View Chart
Dividend Yield % 0.6 0.6 100.3%  

Financials

 STRIDES PHARMA SCIENCE   J.B.CHEMICALS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
J.B.CHEMICALS
Mar-18
STRIDES PHARMA SCIENCE/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,147363 315.9%   
Low Rs642255 251.8%   
Sales per share (Unadj.) Rs317.2169.1 187.6%  
Earnings per share (Unadj.) Rs7.816.6 47.3%  
Cash flow per share (Unadj.) Rs25.123.4 107.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.6 34.6%  
Book value per share (Unadj.) Rs274.3172.5 159.0%  
Shares outstanding (eoy) m89.5083.57 107.1%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.81.8 154.3%   
Avg P/E ratio x114.018.6 612.4%  
P/CF ratio (eoy) x35.713.2 270.5%  
Price / Book Value ratio x3.31.8 182.0%  
Dividend payout %25.512.0 211.6%   
Avg Mkt Cap Rs m80,05825,827 310.0%   
No. of employees `0002.53.8 66.5%   
Total wages/salary Rs m4,3412,511 172.9%   
Avg. sales/employee Rs Th11,325.83,747.4 302.2%   
Avg. wages/employee Rs Th1,731.4665.7 260.1%   
Avg. net profit/employee Rs Th280.1367.8 76.2%   
INCOME DATA
Net Sales Rs m28,39414,135 200.9%  
Other income Rs m941366 257.1%   
Total revenues Rs m29,33414,501 202.3%   
Gross profit Rs m3,9652,178 182.0%  
Depreciation Rs m1,540570 270.4%   
Interest Rs m1,96235 5,622.9%   
Profit before tax Rs m1,4031,940 72.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97552 17.6%   
Profit after tax Rs m7021,387 50.6%  
Gross profit margin %14.015.4 90.6%  
Effective tax rate %6.928.5 24.4%   
Net profit margin %2.59.8 25.2%  
BALANCE SHEET DATA
Current assets Rs m24,83610,470 237.2%   
Current liabilities Rs m18,9932,749 690.9%   
Net working cap to sales %20.654.6 37.7%  
Current ratio x1.33.8 34.3%  
Inventory Days Days7155 128.6%  
Debtors Days Days11378 146.0%  
Net fixed assets Rs m34,2895,811 590.1%   
Share capital Rs m895167 535.6%   
"Free" reserves Rs m23,65114,248 166.0%   
Net worth Rs m24,54614,416 170.3%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43717,649 370.8%  
Interest coverage x1.756.6 3.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.8 54.2%   
Return on assets %4.18.1 50.5%  
Return on equity %2.99.6 29.7%  
Return on capital %6.913.7 50.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6976,164 254.7%   
Fx outflow Rs m7351,334 55.1%   
Net fx Rs m14,9624,829 309.8%   
CASH FLOW
From Operations Rs m1,8711,231 152.0%  
From Investments Rs m5,826-208 -2,799.6%  
From Financial Activity Rs m-10,157-595 1,706.5%  
Net Cashflow Rs m-2,615427 -612.2%  

Share Holding

Indian Promoters % 27.7 55.4 50.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 37.8 3.4 1,115.0%  
FIIs % 8.6 3.9 220.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 37.0 70.0%  
Shareholders   56,241 30,437 184.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 17, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS